JP2021516957A5 - - Google Patents

Info

Publication number
JP2021516957A5
JP2021516957A5 JP2020546320A JP2020546320A JP2021516957A5 JP 2021516957 A5 JP2021516957 A5 JP 2021516957A5 JP 2020546320 A JP2020546320 A JP 2020546320A JP 2020546320 A JP2020546320 A JP 2020546320A JP 2021516957 A5 JP2021516957 A5 JP 2021516957A5
Authority
JP
Japan
Prior art keywords
pcpv
composition
cancer
gene
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516957A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/055744 external-priority patent/WO2019170820A1/en
Publication of JP2021516957A publication Critical patent/JP2021516957A/ja
Publication of JP2021516957A5 publication Critical patent/JP2021516957A5/ja
Priority to JP2024001510A priority Critical patent/JP2024050588A/ja
Pending legal-status Critical Current

Links

JP2020546320A 2018-03-07 2019-03-07 パラポックスウイルスベクター Pending JP2021516957A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001510A JP2024050588A (ja) 2018-03-07 2024-01-09 パラポックスウイルスベクター

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18305237.2 2018-03-07
EP18305237 2018-03-07
EP18306424 2018-10-31
EP18306424.5 2018-10-31
PCT/EP2019/055744 WO2019170820A1 (en) 2018-03-07 2019-03-07 Parapoxvirus vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001510A Division JP2024050588A (ja) 2018-03-07 2024-01-09 パラポックスウイルスベクター

Publications (2)

Publication Number Publication Date
JP2021516957A JP2021516957A (ja) 2021-07-15
JP2021516957A5 true JP2021516957A5 (https=) 2022-03-15

Family

ID=65628796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546320A Pending JP2021516957A (ja) 2018-03-07 2019-03-07 パラポックスウイルスベクター
JP2024001510A Pending JP2024050588A (ja) 2018-03-07 2024-01-09 パラポックスウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001510A Pending JP2024050588A (ja) 2018-03-07 2024-01-09 パラポックスウイルスベクター

Country Status (10)

Country Link
US (1) US12377142B2 (https=)
EP (1) EP3762020A1 (https=)
JP (2) JP2021516957A (https=)
CN (1) CN112512560A (https=)
AU (1) AU2019229653B2 (https=)
BR (1) BR112020018117A2 (https=)
CA (1) CA3093093A1 (https=)
IL (1) IL277161A (https=)
MX (1) MX2020009262A (https=)
WO (1) WO2019170820A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021258008A1 (en) * 2020-06-19 2021-12-23 Immunacor Llc Compositions and methods for treating and preventing viral infection
WO2023083951A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12
CN116121207B (zh) * 2023-02-08 2025-12-12 华南农业大学 一种表达猪圆环病毒3型Cap蛋白的重组羊口疮病毒及其制备方法和应用
WO2024178260A2 (en) * 2023-02-22 2024-08-29 Cornell University Systems and methods for heterologous gene expression by poxvirus vectors
CN116897887A (zh) * 2023-07-31 2023-10-20 湖南中医药大学 一种病毒性哮喘动物模型的构建方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
JP2000507092A (ja) * 1996-02-28 2000-06-13 バイエル・アクチエンゲゼルシヤフト 外来ｄｎａを含むパラポックスウイルス、それらの製造及びワクチンにおけるそれらの使用
KR20000005120A (ko) 1996-03-29 2000-01-25 스칸드레트 존 디 파라폭스바이러스 벡터
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
JP2003523320A (ja) 1999-09-29 2003-08-05 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CA2467365C (en) 2001-12-10 2012-11-20 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus
EP2481819A1 (en) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
JP4672659B2 (ja) 2003-07-21 2011-04-20 トランジェーヌ、ソシエテ、アノニム 改善されたシトシンデアミナーゼ活性を有するポリペプチド
CN1984666A (zh) 2004-07-13 2007-06-20 爱库里斯股份有限两合公司 与其他抗病毒剂联合治疗hiv/aids的副痘病毒
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
DK2029756T3 (en) * 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
PT103865A (pt) 2007-10-25 2009-05-15 Univ De Coimbra Nano-transportadores de base lipídica para entrega direccionada de vectores virais e processo para a sua produção
RU2503717C2 (ru) 2007-11-19 2014-01-10 Трансжене Са Поксвирусные онколитические векторы
US9222078B2 (en) 2010-07-01 2015-12-29 Novozymes A/S Bleaching of pulp
AU2011281229A1 (en) 2010-07-20 2013-01-24 Zoetis Llc Parapoxvirus vectors
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
EP4523756A3 (en) * 2015-02-13 2025-05-28 Transgene Immunotherapeutic vaccine and antibody combination therapy
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
KR20230113832A (ko) * 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2021516957A5 (https=)
TWI850282B (zh) 用於治療癌症之質體建構體和使用方法
AU2022203309B2 (en) Recombinant MVA or MVADELE3L expressing human Flt3L and use thereof as immuno-therapeutic agents against solid tumors
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
EP2212696B1 (en) Systems and methods for viral therapy
US10646557B2 (en) Vaccine composition
JP7025339B2 (ja) 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
JP2024050588A5 (https=)
JP7438552B2 (ja) 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用
TWI851676B (zh) 溶瘤病毒用於治療癌症之用途
CN105031618A (zh) 用于细胞因子递送的穹窿体复合物
JP2021533789A5 (https=)
CA3073310A1 (en) Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody
JP2021517814A (ja) 免疫チェックポイント遮断を発現する癌免疫療法のための腫瘍溶解性ワクシニアウイルス
Shakiba et al. Recombinant strains of oncolytic vaccinia virus for cancer immunotherapy
CN117797253A (zh) 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法
WO2024216669A1 (zh) 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用
US20230277624A1 (en) Methods of determining responsiveness to cancer immunotherapy
CN121653082A (zh) 一种重组溶瘤痘苗病毒、制备方法及在制备用于预防或治疗肿瘤的药物中的应用
WO2024062098A1 (en) Recombinant pseudocowpox virus encoding an interleukin-12
CN119367516A (zh) 一种免疫调节因子组合物及其应用
CN118556081A (zh) 用于癌症治疗的编码免疫刺激蛋白的重组正痘病毒载体